LIMNW Liminatus Pharma, Inc. Warrants
$0.04▲ +0.00%
Unknown
Other
Volume 25
Avg Volume (10D) –
Key Metrics & Fundamentals
Market Cap
–
P/E Ratio
–
Div Yield
–%
52W Range
0.04 - 0.04
% vs 50 MA
-24.27%
% vs 200 MA
–%
RSI-14
46.0
MACD Histogram
+0.0000
Beta (1Y vs SPY)
0.41
Free Cash Flow
-$969,999
Gross Rev
$0
Gross Profit
$0
EBITDA
-$1.37M
COGS
–
Operating Exp
$1.38M
Operating Income
-$1.38M
EBIT
-$1.38M
Pretax Income
-$1.41M
Net Income
-$1.41M
Price & Volume History
Loading chart…
Recent News
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
GlobeNewswire · Aug 18, 2026 8:01 PM
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
GlobeNewswire · Aug 13, 2026 11:15 AM
Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline
GlobeNewswire · Jun 30, 2026 8:30 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See LIMNW's money flow as a full page
Social Sentiment
Avg +0.80 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.